Haldol (Haloperidol)

Haloperidol is prescribed for a range of psychiatric and neurological disorders where dopamine blockade is beneficial.

• Management of schizophrenia, including maintenance therapy.
• Treatment of acute psychotic episodes and severe agitation.
• Control of manic episodes associated with bipolar disorder.
• Reduction of motor and vocal tics in Tourette syndrome.
• Adjunctive therapy for severe behavioral disturbances in dementia.
• Short‑term relief of hyperactivity in certain pediatric conditions.

Haloperidol may cause a variety of side effects that differ in frequency and severity.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal upset.
• Blurred vision or ocular discomfort.
• Weight gain or appetite changes.

Serious

• Tardive dyskinesia with persistent involuntary movements.
• Neuroleptic malignant syndrome, a life‑threatening reaction.
• Severe hypotension or cardiac arrhythmias.
• Hyperprolactinemia leading to hormonal disturbances.
• Seizures in predisposed individuals.
• Significant QT interval prolongation.

Before initiating haloperidol, clinicians should evaluate several safety considerations.

• Assess cardiovascular status, especially for QT prolongation risk.
• Review personal or family history of movement disorders.
• Monitor for signs of neuroleptic malignant syndrome during treatment.
• Use caution in patients with hepatic or renal impairment.
• Evaluate pregnancy and lactation status; discuss potential risks.
• Adjust dose in elderly patients or those with dementia-related psychosis.
• Conduct regular laboratory monitoring for electrolytes and blood glucose when indicated.

Haloperidol can interact with other medications, influencing its efficacy and safety profile.

Avoid

• Other dopamine antagonists or antipsychotics that increase extrapyramidal risk.
• Medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution

• CNS depressants, including benzodiazepines and opioids, which may enhance sedation.
• Anticholinergic agents that can mask early signs of extrapyramidal symptoms.
• CYP2D6 substrates that may be affected by haloperidol metabolism.
• Drugs that alter electrolyte balance, potentially worsening cardiac effects.